المؤلفون: Prabir Chakraborti, James D. Wylie, Ann Pope, Ilias Goranitis, Andrew Stanley, Emilio Porfiri, Duncan McLaren, Adam Daunton, Nicholas D. James, Lucinda Billingham, J. Martin Russell, Alison Birtle, Lazaros Andronis, Sharon Beesley, Chris Parker, Darren Barton, Joe M. O'Sullivan, Sarah Pirrie, John Staffurth, Janet E. Brown, Syed A. Hussain, Stuart Collins

المصدر: Andronis, L, Goranitis, I, Pirrie, S, Pope, A, Barton, D, Collins, S, Daunton, A, McLaren, D, O'Sullivan, J M, Parker, C, Porfiri, E, Staffurth, J, Stanley, A, Wylie, J, Beesley, S, Birtle, A, Brown, J E, Chakraborti, P, Hussain, S A, Russell, J M, Billingham, L J & James, N D 2017, ' Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer : results from the TRAPEZE trial (ISRCTN 12808747) ', BJU International, vol. 119, no. 4, pp. 522-529 . https://doi.org/10.1111/bju.13549
Andronis, L, Goranitis, I, Pirrie, S, Pope, A, Barton, D, Collins, S, Daunton, A, McLaren, D, O'Sullivan, J M, Parker, C, Porfiri, E, Staffurth, J, Stanley, A, Wylie, J, Beesley, S, Birtle, A, Brown, J E, Chakraborti, P, Hussain, S A, Russell, J M, Billingham, L J & James, N D 2016, ' Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747) ', BJU International . https://doi.org/10.1111/bju.13549

مصطلحات موضوعية: Oncology, Male, Cost effectiveness, Cost-Benefit Analysis, Zoledronic Acid, law.invention, zoledronic acid, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Medicine, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, health care economics and organizations, Bone Density Conservation Agents, Diphosphonates, 030503 health policy & services, Imidazoles, cost-effectiveness analysis, Cost-effectiveness analysis, Sr89, Prostatic Neoplasms, Castration-Resistant, Docetaxel, 0305 other medical science, medicine.drug, bone protecting treatments, medicine.medical_specialty, Urology, Bone Neoplasms, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, business.industry, R1, United Kingdom, Surgery, Clinical trial, Zoledronic acid, quality of life, Strontium, Concomitant, Quality of Life, Radiopharmaceuticals, business, castrate-refractory prostate cancer

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d837e51b7a730086c506526e2bbf9d
https://orca.cardiff.ac.uk/id/eprint/94920/1/Andronis_et_al-2016-BJU_International.pdf

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.